Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program.
Head and neck cancer is the fifth most common cancer in the United States, with an overall survival rate of approximately 40-50%. In an effort to improve patient outcomes, research efforts designed to maximize benefit and reduce toxicities of therapy are in progress. Basic research in cancer biology has accelerated this endeavor and provided preclinical data and technology to support clinically relevant advances in early detection, prognostic and predictive biomarkers. Recent completion of the Human Genome Project has promoted the rapid development of novel "omics" technologies that allow more broad based study from a systems biology perspective. However, clinically relevant application of resultant gene signatures to clinical trials within cooperative groups has advanced slowly. In light of the large numbers of variables intrinsic to biomarker studies, validation of preliminary data for clinical implementation presents a significant challenge and may only be realized with large trials that involve significant patient numbers. The Radiation Therapy Oncology Group (RTOG) Head and Neck Cancer Translational Research Program recognizes this problem and brings together three unique features to facilitate this research: (1) availability of large numbers of clinical specimens from homogeneously treated patients through multi-institutional clinical trials; (2) a team of physicians, scientists, and staff focused on patient-oriented head-and-neck cancer research with the common goal of improving cancer care; and (3) a funding mechanism through the RTOG Seed Grant Program. In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG.
Chung
Christine H
CH
Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group: Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA. Christine.Chung@Vanderbilt.edu
Wong
Stuart
S
Ang
K Kian
KK
Hammond
Elizabeth H
EH
Dicker
Adam P
AP
Harari
Paul M
PM
Le
Quynh-Thu
QT
D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000378:metabolism; D035843:Biomedical Research; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000628:therapy* / Q000821:virology; D015687:Cell Hypoxia; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000628:therapy* / Q000821:virology; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D040901:Proteomics / Q000379:methods; D012109:Research Support as Topic; D014015:Tissue Banks / Q000458:organization & administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors